Eli Lilly has announced an additional $4.5 billion investment to expand two of its three manufacturing facilities under development in Lebanon, Indiana, bringing its total capital commitments in the state since 2020 to more than $21 billion. The announcement was made on Wednesday during a ribbon-cutting ceremony for the company’s genetic medicine facility, the first of three planned plants at the Lebanon campus to become operational.
The Lebanon site, located about 28 miles northwest of Lilly’s headquarters in Indianapolis, spans 600 acres within the LEAP Research and Innovation District. Construction began in April 2023, and the company has described the complex as a “cornerstone” of its broader U.S. manufacturing expansion. Since the start of the decade, Lilly has committed over $50 billion to strengthening its domestic production capabilities.
According to the company, the additional investment is intended to address changes in product demand and developments in its pipeline. The funding will support enhancements to the genetic medicine facility, known as Lilly Lebanon Advanced Therapies, as well as the Lilly Lebanon API plant, which remains under construction.
The API facility is expected to manufacture tirzepatide-based treatments, including Mounjaro for diabetes and Zepbound for obesity. Lilly stated that, upon completion, the site will be the largest active pharmaceutical ingredient production facility in the United States. The new funding will also support the planned production of Foundayo, a once-daily oral GLP-1 obesity treatment, and retatrutide, an investigational therapy in late-stage development.
Lilly Lebanon Advanced Therapies is designed to handle both clinical and commercial production of genetic medicines. The company stated that designing and building for these therapies required developing new manufacturing processes due to the absence of established commercial precedent.
A third facility at the site, the Lilly Medicine Foundry, is scheduled for completion in 2027. First announced in 2024 with a planned investment of $4.5 billion, the 1.2 million-square-foot plant will combine research and development with clinical trial manufacturing. It is expected to produce small molecules and biologics for conditions including cancer, diabetes, and Alzheimer’s disease.
“Lilly’s legacy of firsts in Indiana continues today, and the best measure of that legacy is what we do next,” said CEO David Ricks.
In a separate statement, Ricks said the Lebanon API facility, once operational in 2027, is expected to be the largest API production site in U.S. history and that the company chose to build it domestically.
Local and state governments have contributed to the Lebanon campus. Lilly also cited an upcoming report from Indiana University’s Kelley School of Business, which indicates the company accounts for 70% of Indiana’s pharmaceutical GDP and that each Lilly job supports more than two additional jobs across the state.
Beyond Indiana, Lilly previously announced plans to invest $27 billion in four U.S. manufacturing facilities. These include API plants in Virginia, Alabama, and Houston, Texas, as well as a $3.5 billion injectables facility in Pennsylvania. Across the pharmaceutical sector, companies have announced increased U.S. manufacturing investments, with total commitments reaching $370 billion in 2025, according to a report from DPR Construction.
Eli Lilly and Company has announced another major manufacturing investment, with Lilly adding $4.5 billion to its Indiana expansion plans. This latest commitment pushes Lilly’s total U.S. manufacturing investments beyond $50 billion, highlighting the company’s aggressive strategy to strengthen domestic production capabilities and support future demand for innovative medicines.
Lilly’s Indiana Expansion Strategy
Lilly’s investment will support the construction and expansion of advanced pharmaceutical manufacturing facilities in Indiana.
The new facilities are expected to incorporate cutting-edge manufacturing technologies designed to improve efficiency, scalability, and product quality. Automation, artificial intelligence-driven monitoring systems, and digital production platforms are becoming central components of modern pharmaceutical manufacturing.
These technologies help reduce operational errors, increase production speed, and ensure consistent compliance with strict regulatory standards. Smart manufacturing systems can also provide real-time analytics, enabling faster decision-making and predictive maintenance.
Rising Demand for Biopharmaceutical Production
The rapid growth of biologic medicines, injectable therapies, and complex drug formulations has significantly increased the need for specialized manufacturing infrastructure. Modern production facilities require advanced cleanroom environments, highly controlled processes, and sophisticated quality assurance systems.
Expanding domestic capacity allows pharmaceutical companies to better manage rising global demand while maintaining tighter control over distribution and supply timelines.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
